AtaGenix Laboratories
AtaGenix Laboratories
AtaGenix provides CHO transient expression for rapid production of recombinant proteins, antibodies, and Fc-fusion proteins with native mammalian post-translational modifications. CHO-K1 host cells deliver complex N-linked glycosylation, correct disulfide bond formation, and proper folding — essential for therapeutic candidates, SPR/BLI binding studies, and preclinical in vivo experiments.
Standard CHO transient expression delivers milligram-to-gram quantities with turnaround as fast as 2 weeks from plasmid to purified protein. For difficult-to-express targets, our proprietary XtenCHO™ high-density system sustains near-100% cell viability over 15-day cultures, pushing transient yields to 500–1,500 mg/L — approaching stable pool performance without the 12-week cell line development timeline.
Every project includes codon optimization, vector construction, transfection, Protein A/G or Ni-NTA purification, and a comprehensive QC package (SDS-PAGE, SEC-HPLC, endotoxin, concentration). PhD-level scientists manage your project with full IP ownership transfer. Need long-term supply? We can seamlessly transition your lead molecule from transient to stable cell line development.
CHO is the industry-standard mammalian host for therapeutic antibody production. Transient CHO expression gives you manufacturing-representative material in weeks — the glycan profile your molecule will carry at commercial scale.
Service Scope
| ✓ Gene synthesis & codon optimization for CHO | ✓ Expression vector construction (single or dual HC/LC) |
| ✓ CHO-K1 standard or XtenCHO™ high-density host | ✓ Serum-free, chemically defined media |
| ✓ Transient transfection (PEI-based) | ✓ Fed-batch culture optimization (5–15 day runs) |
| ✓ Protein A/G + polishing purification | ✓ Endotoxin removal available (<0.1 EU/µg) |
| ✓ Full QC: SDS-PAGE, SEC-HPLC, endotoxin, A280 | ✓ Multiple tag options (His, Fc, Flag, etc.) |
| Use Case | Why CHO Transient |
| Therapeutic antibody leads | CHO glycosylation matches future manufacturing profile — no glycan surprises at CMC stage |
| Fc-fusion proteins & receptor ectodomains | Correct Fc glycosylation and disulfide bonds for functional receptor binding and PK studies |
| SPR/BLI binding & preclinical studies | High-purity, low-aggregate, low-endotoxin protein matching the commercial production host |
| Multi-candidate screening | Express 5–10 variants in parallel, select winners before investing in stable cell lines |
A standardized 5-step pipeline from your sequence to purified, QC-verified protein. Standard CHO-K1 or XtenCHO™ — same workflow, different engine.
01
Gene & Vector
Codon optimization for CHO
HC/LC vector construction
Sequence confirmation
02
Transfection
CHO-K1 or XtenCHO™
PEI-mediated delivery
Serum-free conditions
03
Culture & Harvest
5–15 day fed-batch
Feed supplementation
Supernatant harvest
04
Purification
Protein A/G or Ni-NTA
SEC polishing
Buffer exchange
05
QC & Ship
SDS-PAGE, SEC-HPLC
Endotoxin (LAL)
CoA + cold-chain ship
Both use CHO-K1 host cells with the same QC standards. The choice comes down to your target's difficulty and how much material you need.
| Factor | Standard CHO-K1 | XtenCHO™ |
|---|---|---|
| Typical Yield | 100–300 mg/L | 500–1,500 mg/L |
| Culture Duration | 5–7 days | Up to 15 days |
| Viability at Harvest | 60–80% | >90% |
| Difficult Proteins | Standard targets, routine mAbs | Optimized for hard-to-express |
| Best For | Early screening, small-scale feasibility | Preclinical material, gram-scale needs |
Ready to scale? Transition directly to aCHO Stable Cell Line — same host, same vector backbone, no re-optimization. Or explore HEK293 Transient when human-type glycosylation is required.
Timelines assume customer-provided plasmid or gene sequence. Gene synthesis adds 3–5 business days. XtenCHO™ timeline extends to ~3 weeks for 15-day cultures. Yields are target-dependent. Quote-based pricing.
Contact Us
+86-27-6552-3339
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
